According to statistics, patients with gastric cancer treated in the United States, Europe, and Japan are often recommended to use ramucirumab in combination with other drugs to treat gastric cancer.T...
What to do about drug resistance of non-small cell lung cancer targeted drugs, you want to know hereLung cancer is the cancer with the highest morbidity and mortality in China. About 1.6 million peopl...
Lung cancer immunotherapy, lung cancer immunotherapy, lung cancer PD-1 treatment, and lung cancer PD-L1 treatment are all you want to know. In the past two years, immune checkpoint inhibitors have un...
Dong-Wan Kim scholars from the Seoul National University Hospital in South Korea will give an oral report on the special meeting of metastatic non-small cell lung cancer at the 52nd Annual Meeting of ...
Lung cancer and proton therapyThe lungs are adjacent to some of the most sensitive and important organs and tissues, including the heart, esophagus, and spinal cord. Only about 20% of lung tumors can...
Lung cancer is one of the most common causes of human death due to tumors, and its morbidity and mortality rate have ranked first in cities. The pathology is mainly non-small cell lung cancer (NSCLC)...
The results of the LUX-Lung 7 study show that a head-to-head Phase IIb clinical study compared afatinib and gefitinib in the treatment of tumors with EGFR mutations The results are published in the "L...
The second edition of the 2016 NCCN Guidelines for Small Cell Lung Cancer (V2.2016) mainly updates the following parts based on V2.2015:Lung cancer preliminary assessment stage updateSCL-2: Some patie...
Registration: ClinicalTrials.govLast updated: January 25, 2016Main ID: NCT02659059Registration Date: January 15, 2016Main sponsor: Bristol-Myers SquibbOpen topic: Nivolumab plus Ipilimumab as a first-...
The US FDA today approved the official launch of AstraZeneca's new drug AZD9291! The trade name and common name of AZD9291 are called Tagrisso or Osimertinib. This is the third generation of TKI tar...